Drugs regulator chief’s press conference today, approval of Covid-19 vaccines likely | Latest News India - Hindustan Times
close_game
close_game

Drugs regulator chief’s press conference today, approval of Covid-19 vaccines likely

Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Meenakshi Ray
Jan 03, 2021 09:13 AM IST

The development comes after the subject expert committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) recommended Oxford-AstraZeneca’s vaccine for emergency use and Covaxin for restricted use.

The chief of India’s drugs regulator will address a press conference on Sunday, a day after its experts recommended that the Oxford-AstraZeneca and Bharat Biotech vaccines against the coronavirus disease (Covid-19) be allowed for emergency use in the country, reports have said. The Drugs Controller General of India (DCGI) will speak with at 11am and according to reports the watchdog may formally announce the approval for these two vaccines.

An employee in personal protective equipment (PPE) removes vials of AstraZeneca's Covishield from a visual inspection machine inside a lab at Serum Institute of India in Pune in this file photo.(REUTERS)
An employee in personal protective equipment (PPE) removes vials of AstraZeneca's Covishield from a visual inspection machine inside a lab at Serum Institute of India in Pune in this file photo.(REUTERS)

The development comes after the subject expert committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use. Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Hindustan Times - your fastest source for breaking news! Read now.

Also read | All you need to know about Bharat Biotech Covid-19 vaccine’s efficacy, price

The recommendations by the SEC have been sent to DCGI VG Somani, who heads Central Drugs Standards and Control Organisation (CDSCO). “The approval is confirmed. It’s now a mere formality for the national drugs controller to put out an order,” said a senior health ministry official, who asked not to be named.

The country’s top drug regulator had indicated earlier this week that India is likely to get a vaccine against Covid-19 in the New Year. “We will have a Happy New Year with something in hand, that’s all I can hint at,” VG Somani, DCGI, had said on Thursday.

Also read | India approves AstraZeneca’s Covid-19 vaccine

If DCGI grants his nod, India will be among a handful of countries, including the US and UK, that have begun vaccinations. Both the US and the UK too have approved two vaccines, but in their case, all of the candidates have completed the requisite scientific process.

Union information and broadcasting minister Prakash Javadekar had said on Saturday said India is perhaps the only country where four vaccines against Covid-19 are getting ready. “One was approved yesterday for emergency use, Serum’s Covishield,” he said.

Javadekar had told reporters earlier that two other vaccines were waiting to be approved - Zydus Cadila’s ZyCoV-D and Russia’s Sputnik V that are both on trial in India. Six Covid-19 vaccines are undergoing clinical trials in India, including the frontrunners Covishield and Covaxin. There are also ZyCOV-D, which is developed by Cadila Healthcare Ltd in Ahmedabad in collaboration with the Centre’s department of biotechnology, and NVX-CoV2373, which is being developed by Serum Institute in collaboration with Novavax. There are two other vaccines, one manufactured by Biological E Ltd, Hyderabad, in collaboration with MIT, US and the other one developed by Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, US.

Another vaccine is being developed by Bharat Biotech International Ltd in collaboration with Thomas Jefferson University, US, which is at the pre-clinical stages. The trial of Russia’s Sputnik V is also going on by Dr Reddy’s Lab.

Also read | Staff shortfall, improved internet connectivity among issues identified in vaccination dry run

SII’s Covishield, which is based on an adenovirus vector, has shown an efficacy rate of 62% in trials held in the United Kingdom and Brazil. The Bharat Biotech vaccine is based on an inactivated virus platform, one of the oldest known methods to develop an inoculation. This technique has been used historically for several other diseases including Hepatitis A, Influenza, Polio and Rabies.

Also read | Covid-19 vaccine will be available in UP near Makar Sankranti: Yogi Adityanath

All states and Union territories conducted mock inoculation drills in a test run on Saturday ahead of the launch as India is also gearing up to carry out the world’s largest vaccination programme. Union health minister Harsh Vardhan said on Saturday that shots administered in the first phase of India’s inoculation drive will be free of cost. The government aims to vaccinate 300 million people in the high-risk category of the population by July-August in the first phase.

India reported 19,078 new cases of Covid-19 and 224 related deaths in the last 24 hours, according to the Union ministry of health and family welfare on Saturday, which have taken the second worst-affected country’s tally to over 10.3 million.

Unveiling 'Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch Now!

Get Updates on India News, Farmers Protest Live alongwith the Latest News and Top Headlines from India and around the the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, February 22, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On